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The accumulation of extracellular amyloid-beta (Aβ) peptide and intracellular neurofibrillary tangles in the brain are two major
neuropathological hallmarks of Alzheimer's disease (AD). It is thought that an equilibrium exists between Aβ in the brain and in the
peripheral blood and thus, it was hypothesized that shifting this equilibrium towards the blood by enhancing peripheral clearance might
reduce Aβ levels in the brain: the ‘sink effect’. We tested this hypothesis by intraperitoneally injecting APP/PS1 transgenic mice with small
unilamellar vesicles containing either phosphatidic acid or cardiolipin over 3 weeks. This treatment reduced significantly the amount of Aβ
in the plasma and the brain levels of Aβ were lighter affected. Nevertheless, this dosing regimen did modulate tau phosphorylation and
glycogen synthase kinase 3 activities in the brain, suggesting that the targeting of circulating Aβ may be therapeutically relevant in AD.
From the Clinical Editor: Intraperitoneal injection of small unilamellar vesicles containing phosphatidic acid or cardiolipin significantly
reduced the amount of amyloid-beta (Aß) peptide in the plasma in a rodent model. Brain levels of Aß were also affected - although to a lesser
extent - suggesting that targeting of circulating Aß may be therapeutically relevant of Alzheimer's disease.
© 2015 Elsevier Inc. All rights reserved.
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tangles.1 Amyloid plaques mainly contain the amyloid-beta (Aβ)
peptide that is released by the proteolytic cleavage of the amyloid
precursor protein (APP).2 Aβ, primarily containing 40 or 42 amino
acid residues (Aβ1-40 and Aβ1-42, respectively), can form
monomers, oligomers, fibrils and plaques.3 However, the oligomers
are believed to be the most toxic form of the Aβ peptide.4
Most cases of AD pathology are idiopathic (of unknown
cause), although a small proportion of cases are genetic and
known as the Familial Alzheimer Disease (FAD). FAD may be
either late or early onset, and it is generally caused by mutations
in the APP,5 Presenilin 16 or Presenilin 27 genes. Transgenic
mouse models expressing one or two of these human mutations
have been developed and used as models of FAD. In these
transgenic mouse models, the expression of human APP with a
single or double mutations, leads to the accumulation of Aβ andnjections of liposomes containing phosphatidic acid and cardiolipin reduce
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evident in the brain of AD patients. Thus, these transgenic AD
models would appear to be useful tools to evaluate the potential
of therapeutic agents that target Aβ. In fact, different therapeutic
approaches have been assessed in these models of AD and
in some cases; reductions of the final amyloid burden have
been reported.8-10
In its protective role, the blood brain barrier (BBB) complicates
the delivery of many potentially important therapeutic drugs. To
reduce Aβ levels in the brain we can avoid the BBB because it
was hypothesized that a dynamic equilibrium exists between the
brain and peripheral pools of Aβ.8 Brain Aβ clearance may be
accomplished through transporter proteins11 and accordingly, the
equilibrium between brain and peripheral Aβ has been adopted as
the basis for several therapeutic interventions. For instance,
sequestering or modifying free peripheral Aβ would shift the
equilibrium towards enhanced efflux, potentially producing a
reduction in brain Aβ and the accumulation of plaques, an
approach that has been referred as the ‘sink-effect’.12,13
Increasing attention has been given to the therapeutic use of
nanoparticles, particularly as vehicles for the delivery and
targeting of drugs.14 Among these, the versatility of liposomes
(LIPs) has drawn considerable attention to their potential uses,
for a very long time in cancer, and more recently in neurological
diseases (for review,15). Indeed, we recently demonstrated that
LIPs with phosphatidic acid (PA-LIP) or cardiolipin (CL-LIP)
incorporated into their bilayer could bind Aβ with high affinity
in vitro.16 Hence, we have used these vesicles to explore whether
the ‘sink-effect’ can be induced in youngAPP/PS1 transgenicmice
following repeated intraperitoneal injection. Our results show that
such treatment significantly reduces the amount of Aβ in the
plasma of mice, while achieving a minor reduction in brain Aβ.
However, these treatments did significantly alter the tau
phosphorylation and GSK3 activity in the brain.Methods
Experimental animals
The double transgenic mice used in the present study
incorporate a human APP construct bearing the Swedish double
mutation and the exon-9-deleted PSEN1 mutation: B6.Cg-Tg
(APPSwe, PSEN1dE9) 85Dbo/J (Jackson Laboratory, Bar
Harbor: stock no. 005864). The genotype of the mice was
confirmed by PCR of DNA isolated from tail biopsies17 and we
used only 3 month old male mice to reduce the variability in the
results. All animal care and handling strictly followed the current
Spanish legislation and guidelines, and those of the European
Commission (directive 2010/63/EU).
Liposome preparation and characterization
Liposomes were composed of Sphingomyelin and Cholesterol
(Sm/Chol, 1:1 molar ratio), containing either 5 mol% of PA or CL.
Small unilamellar vesicles were prepared by repeated extrusion of
the initial multilamellar preparations through polycarbonate filters
(100-nm pore size diameter, Millipore Corp., Bedford, MA), as
described previously.16 The integrity of the liposomes was studiedby measuring the retention of liposome-entrapped fluorescent dye
calcein, as described previously.18 Size, polydispedity index and
Z-potential were determined using a ZetaPlus particle sizer
and ζ-potential analyzer (Brookhaven Instruments Corporation,
Holtsville, NY, U.S.A.).Liposome binding to Aβ peptides
The Aβ1-40 peptide (Phoenix, Inc, USA) was reconstituted
according to the manufacturer's instruction. To obtain a
preparation enriched in Aβ oligomers, the monomeric peptide
solution was diluted with phosphate buffered saline (PBS) 1× to
100 μM and left for 48 h at 37 °C. After incubation, large
aggregates of Aβ were removed by ultracentrifugation
(179,000 × g: Beckman Optima Max, Beckman MLS 50 rotor)
for 30 min at room temperature (RT), and the presence of small
soluble aggregates was assessed by AFM, as described.19 The
binding of the Aβ peptides to the liposomes was studied by using
liposomes radiolabeled with [3H]-Sm (0.001 mol% of total
lipids) and through ultracentrifugation on a discontinuous
sucrose density gradient, as described elsewhere.16 The
distribution of lipids along the gradient was followed by
counting the liposome-associated radioactivity by liquid scintil-
lation. The distribution of the peptide was followed by an
established dot-blot procedure16 using mouse monoclonal
antibody 6E10 (1:1000, Signet Dedham, MA). For the Aβ1-40
detection, chemiluminescent spots were semi-quantitatively
estimated using ImageQuant LAS4000 and the proportion of
the bound peptide was expressed as the ratio between the amount
of peptide in fractions 1-5 over the total amount of peptide.16The effect of liposomes on cell proliferation
The possible effect of liposomes on cell proliferation was
evaluated in cultured hCMEC/D3 and human neuroblastoma
SH-SY5Y cells. The hCMEC/D3 cells recovered between passage
25 and 35 were seeded at a density of 27,000 cells/cm2 in tissue
culture flasks coated with 0.1 mg/mL rat tail collagen type 1 and
they were cultured at 37 °C in an atmosphere of 5%CO2/saturated
humidity in EBM-2 medium (Lonza, Basel, Switzerland)
supplemented with: 5% v/v fetal bovine serum (FBS), 1 U/ml
Penicillin, 100 μg/ml Streptomycin, 1.4 μM hydrocortisone,
5 μg/mL ascorbic acid, 1/100 chemically defined lipid concentrate
(Invitrogen), 10 mM HEPES and 1 ng/mL basic FGF (bFGF).20
SH-SY5Y cells were cultured in a 5%CO2 humidified incubator at
37 °C in DMEM supplemented with 10% heat-inactivated FBS,
penicillin (100 U/ml), streptomycin (100 μg/ml), and L-glutamine
(2 mM). The cells were differentiated over 7 days with 10 μM
retinoic acid (RA) dissolved in dimethylsulfoxide (DMSO) and
diluted in culture medium to reach DMSO concentrations
previously demonstrated to be non-toxic.21
Cells were exposed to liposomes (6 to 120 μg lipid/mL) for
24 h at 80%-90% confluence and untreated cells were used as a
negative control. After incubation with liposomes, proliferation
was evaluated by the MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide]) assay,22 and each sample was
analyzed in triplicate.
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Transgenic male mice (3 months old, n = 7 per group)
were injected intraperitoneally with 50 μl (2.5 mmol) of
each liposome preparation every other day for three weeks.
There were four treatment groups: phosphatidic acid-liposome
(PA-LIP), cardiolipin-liposome (CL-LIP), Plain-liposome (LIP)
and PBS as controls. Two wild-type mice were included in each
group to evaluate possible toxic effects and no mice displayed
adverse effects in any of the assays. Two independent experiments
were performed and the results are presented as the mean of all
mice analyzed.
Blood and tissue sampling
Blood samples were taken before (t0) and after the treatment (at
the end-point, 24 h after the last injection point) by submandibular
vein puncture.23 After mixing with 10 mMEDTA in PBS 1:1, the
blood was centrifuged for 5 min at 10,000 × g at RT to obtain
plasma,24 which was stored at −80 °C.
Mice were sacrificed in CO2 and a necropsy was performed
by personnel expert in handling laboratory animals. The brains
were removed and split into two hemibrains, as described
previously.25 Briefly, one hemibrain was snap frozen on dry ice
for subsequent homogenization and stored at −80 °C. The other
hemibrain was fixed for 24 h in 4% paraformaldehyde (PFA) in
PBS and cryoprotected in graded concentrations of sucrose
(15%-30%) in PBS. The fixed tissue was then set in O.C.T.™
compound (Tissue-Tek® Sakura) and frozen at −80 °C.
Aβ quantification by ELISA (1-40 and 1-42)
Brain tissue was homogenized in 8 vol of ice-cold guanidine
buffer (5 M guanidine HCl/50 mM Tris HCl, pH 8). The
homogenates were mixed for 3 h at room temperature (RT)
and stored at −20 °C. Brain homogenates were diluted 1:50 in
albumin-PBS-Tween buffer (5% v/v Bovine Serum Albumin,
0.03% w/v Tween-20 in PBS) prior to centrifugation at
16,000 × g for 20 min at 4 °C. The amyloid levels were
measured in plasma samples and diluted brain supernatants
with an Aβ40 or Aβ42 Human ELISA kit (Invitrogen, USA)
according to the manufacturer's instructions. The absorbance in
the plates was read at 450 nm on an Opsys MRmicroplate reader
(Dynex Technologies, USA).
Complement assay
The details of the serum preparation, characterization and
functional assessment of complement pathways were as
indicated in our previous studies.26 Due to the substantial
biological variation of complement proteins in serum, and the
large number of positive and negative feedback interactions, we
separately assessed the generation of complement activation
products in the sera from five healthy individuals.27
Gel electrophoresis, Western blotting and immunodetection
Brain tissue was homogenized in 3 vol of ice-cold lysis buffer
(20 mM Hepes, 100 mM NaCl, 100 mM NaF, 1 mM NaVO4,
5 mM EDTA, 1% Triton X100) with proteases inhibitor cocktail
(Roche Diagnostic) and 1 μM okadaic acid (Calbiochem) asphosphates inhibitor. The homogenate was then centrifuged at
4 °C for 20 min at 16,000 × g and the supernatant was isolated.
The protein concentration was measured using the BioRad DC
Protein Assay (BioRad) following the manufacturer’s protocol
and prior to resolving the proteins, loading buffer (10% SDS,
0.5 mM DTT, 325 mM TrisHCl [pH 6.8], 87% glycerol,
bromophenol blue) was added to the supernatants. Protein
extracts of the brain homogenates were resolved on sodium
dodecyl sulphate polyacrylamide gels (SDS/PAGE: 20 μg
protein/lane), and transferred to a nitrocellulose membrane
(Whatman, Germany). The membrane was incubated in a 10%
(w/v) solution of non-fat milk for 1 h at RT. After overnight
incubation at 4 °C with the primary antibody (more detail in
supplementary section), the blots were washed in 0.1% w/v
Tween-PBS and incubated with the horseradish peroxidase
conjugated secondary antibody (Santa Cruz Biotechnology,
USA), which was detected by Western Lightning™ Chemilu-
minescence (Perkin Elmer, USA). β-Actin served as the internal
control and the intensity of each band was determined with
ImageJ™ software (NIH, USA).
Immunofluorescence studies
Freezing cryostat coronal sections (30 μm) of fixed hemi-
brains were obtained around Bregma-2 (Leica, Germany). To
perform immunofluorescence assays, pretreated slices with
formic acid 70% were incubated with the primary antibodies,
6e10 (1:1000, COVANCE) and GFAP (1:500, Promega)
overnight at 4 °C. After that, the sections were washed and
incubated with anti-rabbit Alexa 488 and anti-mouse Alexa 555
conjugated secondary antibodies (Invitrogen). After washing,
DAPI was used to label the cell nuclei and the sections were
mounted with Fluoromount G (Southern Biotech). Finally,
sections were visualized by fluorescence microscopy (Axio-
vert200, Zeiss) and images were captured using a SPOT RT
Slider camera (Diagnostic). Analyses were performed using
ImageJ™ software.
Statistical analyses
Sigma Plot software was used for all statistical analyses.
Student's t-test was used to compare results in paired groups,
treated (PA-LIP or CL-LIP) and control (LIP + PBS). In all
cases, differences were considered statistically significant when
P ≤ 0.05 (*), P ≤ 0.01 (**) or P ≤ 0.001 (***).Results
Characterization of liposomes
Based on three independent measurements, the mean
liposomes size was 102 ± 2 nm and they remained stable for
72 h. The polydispersity index of the liposomes was 0.01
and when assessed by DLS, the calculated ζ-potential values
were −25.06 ± 1.5 mV for plain-liposomes and −28.55 ±
1.2 mV for liposomes carrying PA or CL. Calcein-entrapped
liposomes were stable and retained their content over 24 h incubation
in cell culture medium or human plasma (data not shown).
Figure 1. Binding of liposomes to Aβ peptide by ultracentrifugation
assay. (A) AFM analysis of Aβ1-40 aggregates. A representative 4 × 4-μm
x-y, 2-nm total z-range AFM image is shown. Bar: 500 nm. (B) The peptide
distribution along the gradient fractions was followed by a dot-blot procedure
and a representative dot-blot is shown. (C) The proportion of peptide bound
to liposomes was expressed as indicated in the text. Results show the
means ± s.e.m. (n = 3).
Figure 2. Liposome-mediated complement activation in human serum.Panels
(A) and (B) compare the liposome-mediated rise of serum anaphylatoxin
C5a and the soluble complement activation product SC5b-9 in the serum
from five healthy individuals (S1-S5), respectively. In all tests, the liposome
concentration was 3.5 mg total lipid/mL serum, and in all the sera, zymosan
(1 mg/mL) treatment generated more than 35 μg/mL and 1200 ng/mL
SC5b-9 and C5a, respectively: *P ≤ 0.05 compared with background and
liposomes containing 5 mol% PA in their bilayers (saline-treated serum).
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The binding of PA and CL functionalized liposomes to
Aβ1-42 has been established previously.
16 Liposome binding
to Aβ1-40 or Aβ1-42 (as positive control) was assessed by
ultracentrifugation on a discontinuous sucrose density gradient,
measuring the amount of peptide bound to the liposomes. PA or
CL liposomes enriched vesicles bound approximately 25% of
either of the peptides tested (Figure 1).
In vitro evaluation of the effect of liposomes on cell viability
The effects of different doses of liposomes on hCMEC/D3
and SH-SY5Y cell proliferation were determined using the
MTT assay. None of the liposomes tested altered the
proliferation of either cell type at the lipid concentrations tested
(data not shown).
Activation of the complement system
We tested whether Aβ binding liposomes can trigger
complement activation in human sera. Liposomes containing
either 10 mol% PA or 5 mol% CL activated complement in all
the sera tested, as evident through the rapid rise in both C5a
anaphylatoxin and SC5b-9 (the vitronectin-bound form of the
membrane attack complex C5b-9) above background levels
(Figure 2). However, lowering the proportion of PA to 5 mol%neither compromised Aβ-binding16 nor induced complement
activation (Figure 2). Indeed, even when human serumwas spiked
with Aβ1-40 (5 μg/mL serum), the addition of Aβ-binding PA
(5 mol%) liposomes did not trigger complement activation (data
not shown).
Effect of liposome administration on plasma and brain Aβ levels
To determine the basal level of Aβ1-40 and Aβ1-42, blood and
plasma were obtained before commencing the injection regime
(t0), and the putative effect of the treatment was ascertained in
samples taken at the end-point (tf), 24 h after the last injection.
The results, represented as tf-t0 (Figure 3, A-B), highlighted a
significant reduction in both Aβ1-40 and Aβ1-42 in plasma after
PA-LIP and CL-LIP administration. PA-LIP provoked a 6-fold
reduction in Aβ1-40 (P b 0.05) and a 3-fold decrease in Aβ1-42
(P b 0.05). Higher reductions in Aβ1-40 and Aβ1-42, 10- and
7-fold respectively, were evident in CL-LIP treated mice
(P ≤ 0.001 and P b 0.05).
The effects of both types of liposomes on brain amyloid burden
were also tested using the same ELISA kit. The results showed
decreasing levels in bothAβ1-40 andAβ1-42 burden in animals that
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Figure 3. Amyloid-β in the plasma and brain of the treated transgenic mice.(A-B) The reduction of human Aβ1-40 and Aβ1-42 in plasma is shown as the
difference between post- and pre-treatment levels (tf-t0) in pg/ml of plasma. (C-D) Human Aβ1-40 and Aβ1-42 burden in the brain evident through the direct
determination of the final amount of peptide in the brain of the treated mice in ng/mg of brain mass. The graph represents the mean ± s.e.m.
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treated mice showed similar results in Aβ1-40 levels (p = 0.06),
however Aβ1-42 was not statistically significant (Figure 3, C-D).
The number, size and distribution of plaques are important
parameters in AD that can be altered by therapeutic intervention.
To confirm the ELISA results and to better understand the effects
of the liposomes, immunofluorescence analysis was performed
on fixed brain tissue (Figure 4). The presence of amyloid
deposits (red spots indicated by white arrowheads) appeared to
be more prominent in the control animals, however these
differences were not statistically significant (Figure 4). Similarly,
the number of GFAP-expressing cells (green) at this age was not
sufficiently high to observe qualitative differences between
treatments. These data were corroborated in Western blots.
Differences in Aβ production
We determined whether the holoAPP, its proteolytic products
or other elements relevant in the generation of Aβ, such as
BACE, were modified by the administration of the liposomes.
No major differences in total APP levels (22C11) or of its
products (6E10) were evident in western blots among mice
treated with LIP, CL-LIP or PA-LIP (Figure 5, A). Similar levels
of BACE were found in all groups, suggesting that the activity of
this enzyme and APP proteolysis were not affected. These data
confirm that amyloid peptide production was not modified by
changes in either holoAPP protein or that of BACE.Synaptic alterations and glial reaction
Any treatment for Alzheimer's disease should improve synaptic
activity and thus, we tested the effect of liposome treatment on some
synaptic markers like PSD95, P-synapsin and p120. No major
differences in PSD95 were evident in western blots (Figure 5, B),
although themore p120was evident in themice treatedwith CL-LIP
(P ≤ 0.01) or PA-LIP (not statistically significant).
In the transgenic mouse strain studied here a glial reaction
around the plaques is normally detected and this reaction
augments as the density of plaques increases.25 However, we
found no modification in the glial reaction by immunofluores-
cence or in western blots comparing treated and control groups
(Figures 4 and 5, B).
Effect of the liposomes on Tau phosphorylation
We finally evaluated the tau protein and its phosphorylation
using specific antibodies. This post-translational modification is
regulated by a plethora of kinases28,29 and some phosphatases.30
We found that the degree of tau phosphorylation was modified
by treatment with either PA-LIP or CL-LIP and we detected a
statistically significant reduction in the level of AT100 and
AT270 (Figure 6, A) after treatment with either PA-LIP
(P b 0.01) or CL-LIP (P b 0.001). By contrast, there were no
major differences in the internal controls (total tau-pan-tau- and
β-actin). We tried to correlate the differences observed with
altered kinase and phosphatase activity relevant to tau29,30 but no
CA1
CA1 CA1
Cx
Cx
CxC CL
6e10
GFAP
PA
6e10
GFAP
6e10
GFAP
6e10
GFAP
6e10
GFAP
6e10
GFAP
0
0.1
0.2
0.3
Co PA CL
Area occupied by Aß plaques (%)
A B
Figure 4. Immunofluorescence analyses of the treated and control mice brain.(A) Coronal fixed section from a brain treated with liposomes containing PA, CL
or with plain-liposomes (control) and stained with an antibody against APP (6E10, red) and GFAP (green). In addition, the sections were counter-stained with
DAPI (blue). In the section, arrowheads indicate the accumulation of amyloid (red spots) in regions of the cortex (Cx) or hippocampus (CA1). (B) Percentage of
the brain area occupied by plaques showed not statistically significant differences between groups.
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determined the amounts and activation status of GSK3, SAP/
JNK and p38MAPK, using specific antibodies and phospho-
antibodies. Our data showed that pGSK3Tyr 216/276 and pSAP/
JNKTyr138/185 were significantly diminished (Figure 6, C) by
exposure to PA-LIP (P b 0.01) and CL-LIP (P b 0.05).Discussion
In this study we have assessed the benefits that may be gained
by administering liposomes that can bind to Aβ and initiate the
“sink effect” in a mouse model of AD. While intraperitoneal
injection of a small fraction of liposomes will be cleared by
resident macrophages in the peritoneal cavity, at higher
concentrations a significant fraction of vesicles can drain through
the stomata in the diaphragm to reach the lymphatic system, and
eventually the bloodstream.31 From the stomata, the peritoneal
fluid enters the subperitoneal lymphatic lacunae. The principal
route of extrinsic lymphatic drainage is via parasternal lymphatic
trunks that carry lymph and suspended vesicles to the parasternal/
mediastinal lymph nodes and ultimately, to the right lymphatic or
upper terminal thoracic duct. By contrast, liposome extraction by
macrophages in the regional lymph nodes remains marginal.32,33
The anionic liposomes we used are well known to be cleared by
macrophages of the reticuloendothelial system.34 Here, possible
accelerated clearance could even enhance Aβ translocation to
macrophages. For these reasons, we introduced liposome
intraperitoneally (slow appearance in the blood) to allow
gradual interaction with Aβ. Accordingly, peritoneal injection
may represent a convenient way to repeatedly administer liposomes
and their introduction into the bloodstream.
Our results in vivo clearly show that both liposome treatments
can reduce Aβ levels in the circulating blood pool. This further
confirms the ability of these liposomes to interact sufficiently
with Aβ prior to their rapid clearance by hepatic and splenic
macrophages. Our hypothesis is that liposomes act by removingthe peripheral Aβ peptides (in the blood circulation) drawing out
the central soluble Aβ aggregates.
Indeed, anionic liposomes are prone to complement
opsonization31 and clearance by macrophages in contact with
blood.35 However, we were able to overcome complement activation
by PA containing liposomes by reducing the PA content to 5 mol%
without compromising their Aβ-binding properties. Indeed, these
liposomes still failed to trigger complement activation even after
Aβ binding. This is also advantageous, since inadvertent activation
of the complement system can elicit acute and pro-inflammatory
responses. Indeed, such reactions have been noted following
infusion of many nanomedicines to animals and humans.35,36
It has been suggested that soluble Aβ can cause abnormal
vascular reactivity in the absence of vascular deposition or vessel
wall dysfunction.37 Therefore, it is tantalizing to propose that
liposome-mediated reduction of Aβ in the blood could represent
a suitable therapeutic strategy to prevent frequent strokes due to
the amyloid deposition in small arteries and capillaries in vessels
affected by amyloidosis.38
In these experiments we have used the APP/PS1 transgenic
mouse line, one of the most extensively studied mouse models of
AD.39 This line has been amplified and characterized over the past
4 years and during this period, we have detected the presence of
Aβ1-40 and Aβ1-42 in blood and brain, as well as the presence of
amyloid plaques and their increase as adult mice mature (data not
shown). Thus, we were aware that mild amyloid deposits appear in
the brain ofmice in our colony at 3 months-of-age. Plaques augment
exponentially for somemonths (number, area and density), reaching
a plateau at around 9-12 months with a slower increase thereafter
(data not shown). This information suggests that 3 month old
mice represent a good age to begin to treat this transgenic colony and
to study the effect of our formulation on early development of
amyloid plaques.
Following liposome administration, we noticed minor
reductions in the Aβ burden in the brain of the mice, although
these were modest. The amyloid levels in the brain were only
measured after the treatment regime had terminated and
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Figure 5. Western blot analysis of Aβ production and markers of synapses.
Four samples from each group were separated by electrophoresis and
analyzed in western blots. (A) Images showed no major differences in the
full length APP (22C11 and 6E10 antibody). Similarly, no noticeable
differences were detected in BACE or GFAP. (B) Analysis of some synaptic
proteins showed that PSD95 was not modified but there was an increase in
p120 after CL-LIP treatments. β-Actin was used as a loading control.
The graph represents the normalized values of the densitometric analysis
(being the control 100%) represented as the mean ± s.e.m (** P ≤ 0.01).
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treatment on brain Aβ levels and hence, the sink effect. It should
be emphasized that this transgenic mouse model displays
important variations in brain amyloid levels, even among
littermates and independently of age. Therefore, we cannot
rule out that longer treatment could produce better results and a
more important reduction in Aβ brain levels. Moreover, it is
thought that circulating Aβ peptides act as prion-like proteins,
inducing deposition,40 and therefore, any reduction in these
peptides will provoke a decrease in plaque accumulation.
Further, we have examined whether the differences in both
Aβ1-40 and Aβ1-42 levels in plasma were associated with some
key biochemical differences in the brain, and in neurons. We
found no major differences in the levels of proteins responsible
of Aβ production, such as APP or BACE, indicating that the
reduction of Aβ1-40 and Aβ1-42 levels is not due to differences
in the substrate or in the level of its processing. This strongly
indicates that the reduction is due to the clearance of
amyloid rather than its production, in part because BACE
activity has been associated with the amount of protein41 andγ-secretase production is strongly enhanced by the mutated
human transgene (PS1).
These APP/PS1 transgenic mice have been reported to show
disturbances in synapsis independent of the accumulation of
amyloid, possibly due to the overexpression of APP.42 However
this alteration may recover after different treatments43 and we
tested whether liposome administration could reverse such
destabilization of synapses. Accordingly, we have analyzed
one important axonal protein, PSD95, which enhanced the
maturation of synapses,44 and the presynaptic p120 that fulfils an
important role in the stability of cell-cell adhesions.45 We failed
to detect a clear variation in PSD95 levels, despite the fact that
some authors have detected an increase in this protein in APP/
PS1 mice that may compensate for the deficient synaptic
activity.46 On the another hand, p120 is thought to play a central
role in the γ-secretase association and processing of cadherins,
and it may suppress APP processing and Aβ production,
possibly by recruiting γ-secretase to cadherins and thereby,
limiting its availability for the processing of APP.47 The
accumulation of this protein detected in our treated mice, even
being slight, could collaborate in the reduction of Aβ levels in
the brain.
Finally, tau, some phospho-tau epitopes, and some kinases
and phosphatases relevant for tau dynamics were analyzed, given
that tau phosphorylation and its subsequent accumulation as
tangles are the other important hallmarks of AD.48,49 Again our
data showed that some phospho-epitopes of tau, such as PHF-1,
may diminish, yet tau phosphorylation at AT100 and AT270 was
more clearly modified by both liposomes. The differences in
these phospho-epitopes are apparently not due to differences in
PP2A as the activation status of PP2A appears not to be modified
by the treatments. Moreover, the analysis of some kinases
relevant to tau metabolism, such as GSK3 and SAP/JNK,
showed a reduction in Tyr- and Thr/Tyr-phosphorylation after
treatment. In both cases, this phosphorylation correlates with
kinase activation, which was reduced in correlation with the
tau-1 decrease.49,50 It is interesting to note that the CL-LIP and
PA-LIP did not produce similar responses and while PA-LIP
treatment generated weaker p-tau modification, there was a clear
reduction in pGSK3-pTyr and SAP/JKN-pThr/Tyr. By contrast,
the reduction in AT100 and AT270 was more important
following CL-LIP administration, although the modification
of the kinases analyzed was milder. All these biochemical data
suggest that each liposome composition has a distinct impact on
the final effect, which opens many interesting questions about
the secondary effects on other tissues/metabolites that may
generate slightly different brain responses that must be taken
into account.
Together, the data presented here indicate that liposomes
containing PA or CL can alter circulating amyloid and in
addition, directly or indirectly, they can modify brain metabo-
lism. Obviously, whether the reduction in brain amyloid
observed is at least partially due to this metabolic modification
remains unclear. In summary, our data strongly suggest that
liposomes containing PA or CL may serve as interesting
therapeutic agents to reduce Aβ in the peripheral blood and
subsequently, this peripheral reduction in Aβ may modify the
final Aβ levels in the brain.
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Figure 6. Tau, kinases and phosphatases levels in brain extracts.Some representative blots from three repeated experiments normalized with actin (previously
controlled loading with Ponceau staining). (A) Westerns blot of total tau (pan-tau antibody) and some phosphoepitopes of tau (antibodies PHF-1, AT270 and
AT100) using β-actin as a loading control. Major differences were detected in AT100 and AT270 after CL-LIP treatment. The graph on the right represents the
normalized values of AT100 represented as the mean ± s.e.m (** P ≤ 0.01, *** P ≤ 0.001). (B) In western blot analysis of PP2A (total level, methylated or
phosphorylated level of catalytic subunit), no consistent differences were detected during the treatment or in the different groups of mice. β-Actin was used as
loading control. (C) In western blots of some tau kinases and phospho-epitopes of the active or inhibited form of these kinases (Total GSK3, pGSK3 Tyr216/276
and pGSK3Ser9; total p38MAPK and the active p38MAPK Thr180/Tyr182; and the active SAP/JNK Thr183/Tyr185), the activation of GSK3 and JNK was modified
by PA-LIP administration. The graphs on the right represent the normalized values of pGSK3Tyr 216/276 and pSAP/JNK Thr183/Tyr185 presented as the means ± s.d.
(* P ≤ 0.05, ** P ≤ 0.01). β-Actin was used as a loading control.
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